BioCentury | Jul 25, 2019
Clinical News

July 25 Clinical Quick Takes: J&J’s ponesimod hits MS endpoint; plus a CRISPR first, Genkyotex and Aeglea

Janssen’s ponesimod tops Aubagio in Phase III The Janssen Pharmaceuticals unit of Johnson & Johnson (NYSE:JNJ) said it plans to submit NDAs to FDA and EMA this year after reporting ponesimod met the primary endpoint...
BioCentury | Jun 26, 2019
Clinical News

June 25 Clinical Quick Takes: Minerva meets in insomnia; plus Aldeyra, Genkyotex and more

Minerva rises with insomnia data Seltorexant (MIN-202) from Minerva Neurosciences Inc. (NASDAQ:NERV) met the primary endpoint of reducing Latency to Persistent Sleep (LPS) at night 1 vs. placebo (p≤0.001) in a Phase IIb trial to...
BioCentury | May 2, 2019
Clinical News

May 2 Clinical Quick Takes: Biogen, GSK, Celgene/bluebird, Genkyotex

Biogen's ALS candidate reduces SOD1 protein levels in CSF Biogen Inc. (NASDAQ:BIIB) will present on May 7 at the American Academy of Neurology meeting the interim Phase I/II data of tofersen that had prompted it...
BioCentury | Nov 9, 2018
Clinical News

Twice-daily dose of Genkyotex's PBC therapy meets six-week endpoints

Genkyotex S.A. (Euronext:GKTX) reported data from a prespecified interim analysis of 92 evaluable patients with primary biliary cholangitis in a Phase II trial showing that twice-daily GKT831 led to a significant 23% reduction in mean...
BioCentury | Nov 5, 2018
Clinical News

Twice-daily dose of Genkyotex's PBC therapy meets six-week endpoints

Genkyotex S.A. (Euronext:GKTX) reported data from a prespecified interim analysis of 92 evaluable patients with primary biliary cholangitis in a Phase II trial showing that twice-daily GKT831 led to a significant 23% reduction in mean...
BioCentury | Jul 3, 2017
Clinical News

Genkyotex begins Phase II of GKT831 in PBC

Genkyotex S.A. (Euronext:GKTX) began a Phase II trial to evaluate once- and twice-daily 400 mg GKT831 (formerly GKT137831) for 24 weeks in 102 patients with primary biliary cholangitis (PBC) and an inadequate response to ursodeoxycholic...
BioCentury | Apr 6, 2015
Emerging Company Profile

Treating H. pylori

ImevaX GmbH is developing a therapeutic vaccine against Helicobacter pylori that could be more effective than standard of care without generating resistance. The company also is developing two diagnostics for the bacterial infection, including a...
BioCentury | Aug 28, 2014
Distillery Therapeutics

Indication: Inflammation

Indication Target/marker/pathway Summary Licensing status Publication and contact information Inflammation Asthma Helicobacter pylori g-glutamyl transpeptidase (ggt); H. pylori vacuolating cytotoxin (vacA) Mouse studies suggest ggt and vacA can help prevent allergic asthma. In young mice,...
BioCentury | Oct 24, 2013
Distillery Techniques

Technology: Drug platforms

This week in techniques Approach Summary Licensing status Publication and contact information Drug platforms Crystal structures of Staphylococcus aureus penicillin binding protein 2a (PBP2a) In vitro studies identified an allosteric site on PBP2a that could...
BioCentury | Jul 2, 2012
Clinical News

Cysteamine bitartrate: Phase IIb started

Raptor began the double-blind, placebo-controlled, U.S. Phase IIb CyNCh trial to evaluate 600, 750 and 900 mg/day RP103 for 52 weeks in 160 patients ages 8-17 years. NIH's National Institute of Diabetes and Digestive and...
Items per page:
1 - 10 of 15